EUVIMED · CrossrefJournal
Pharmacogenomics
ISSN 1462-2416 · Informa UK Limited
Latest articles
Clinical implementation of pharmacogenetics in inflammatory skin diseases: current evidence and future directions
Prevalence of TPMT and NUDT15 pharmacogenomic variants in a diverse germline testing cohort from India
Genetic determinants of chemotherapy-induced oral mucositis in children with solid malignancies
Global distribution of CYP2C19 variants in clopidogrel-indicated populations: implications for pharmacogenomic-guided antiplatelet therapy
Prescribing prevalence and trends of medications with pharmacogenetic implications: a study based on primary care data in Manitoba, Canada
Organoids for drug sensitivity prediction in urothelial carcinoma
Fall-risk in genetic variable cytochrome P450 enzymes and exposure to anticholinergic drugs – a pilot-analysis from the ADRED-study
From CYP450 pharmacogenomics to personalized medicine: clinical evidence, dosing guidelines, and future perspectives
Mapping the development pipeline of genomic point-of-care tests: a horizon scan
The influence of pharmacogenetics on the treatment-related outcomes of antidepressants and antipsychotics in Brazil: a systematic review
Reduction of next-generation sequencing files for efficient pharmacogenotype extraction
Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care
Adherence to international pharmacogenomic recommendations in pediatric cancer care: a cohort analysis embedded within the MARVEL-PIC randomized trial
Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapy
Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases
Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models
Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use
Closely similar tacrolimus morning troughs and graft function across the recipients’ common ABCB1 polymorphisms ( c.2677G>T/A , c.1236C>T , c.3435C>T ) early after renal transplantation
Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: “It’s no different from your blood type”
The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer
Acute hemolytic anemia and methemoglobinemia in a pediatric oncology patient with G6PD deficiency: a case report
Pharmacogenetics of venlafaxine response in older adults with depression and chronic lower back pain
Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia
Genetics of tardive dyskinesia: a review of progress over the past decade
Exploring the potential of pharmacogenetic testing in Alabama Veterans diagnosed with major depressive disorder
Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients: prevalence of variants with decreased activity and chemotherapy outcomes
ABCG2 and allopurinol response: when pharmacogenetics collides with fixed-dose practice
The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress
A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder
Importance of genetic ancestry in pharmacogenomics for precision medicine
EUVIMED